3 citations
,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” ILC1 cells contribute to hair loss in alopecia areata.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
May 2026 in “Bioorganic Chemistry” 5 citations
,
January 2021 in “Indian Journal of Pharmacology” Nilotinib can cause generalized keratosis pilaris.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
2 citations
,
May 2008 in “Journal of Clinical Oncology” AZD6244 treatment causes skin aging effects by depleting skin stem cells.
1 citations
,
July 2024 in “British Journal of Dermatology” Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
7 citations
,
August 2025 in “European Journal of Endocrinology” Long-term use of calcineurin inhibitors in transplant patients can cause hormone issues that can be managed with proper care.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
November 2022 in “Journal of Investigative Dermatology” Short-term treatment with ROCKi increases skin cell growth without changing stem cell features.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
56 citations
,
September 2016 in “Pharmaceutical Research” The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.
August 1994 in “Journal of dermatological science” Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.
161 citations
,
August 2013 in “Journal of experimental botany” Certain inhibitors slow down plant growth by causing early cell specialization without changing the cell development pattern.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
5 citations
,
July 2024 in “Journal of Microbiology and Biotechnology” ICP5249 helps hair grow by activating a specific cell pathway.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
September 2019 in “Journal of Investigative Dermatology” Innate lymphoid cells type 1 may contribute to alopecia areata.
4 citations
,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
10 citations
,
August 2016 in “Dermatology Online Journal” Nilotinib can cause skin issues like red bumps and hair loss.
ILC1-like cells may contribute to hair loss in alopecia areata.
26 citations
,
June 2024 in “Frontiers in Immunology” SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.
60 citations
,
October 2020 in “Nature Communications” AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.